Source: https://www.academyhealth.org/events/2017-10/state-flexibility-new-era-what-are-research-priorities-ss1115-demonstration-and
Timestamp: 2019-04-22 08:44:57+00:00

Document:
State Flexibility in a New Era: What are the Research Priorities for §1115 Demonstration and §1332 Waiver Evaluations?
With funding from the Robert Wood Johnson Foundation, AcademyHealth hosted this expert meeting to explore research priorities related to the evaluation of Section 1115 Medicaid demonstrations and Section 1332 state innovation waivers.
State health care environments have been undergoing major changes due to Affordable Care Act implementation and will likely see additional modifications under the policy environment of the Trump Administration. It will be important to understand the implications that current and future federal statutory and regulatory requirements and opportunities - particularly through the waiver process) have on states' capacity to support the delivery of high-quality, comprehensive care through their Medicaid program and their commercial insurance markets.
With support from the Robert Wood Johnson Foundation, AcademyHealth convened health services and policy researchers, national and state-level evaluators and policymakers, philanthropic organizations and other experts to discuss the critical issues that need to be addressed in evaluating the impact of waivers on coverage, access to care, effective use of health services and public financing, health outcomes, financial well-being, and employment.
The full agenda and select presentation slides are below.
What Policies and Strategies are Federal and State Policymakers Seeking to Test for the Future of Medicaid using §1115 Waivers?
What goals are these strategies and policies seeking to achieve? What outcomes should be evaluated? Is there a useful way to categorize/group policy goals (e.g., health savings accounts, health behavior incentives, cost sharing requirements; tying benefits/eligibility to work requirements; making Medicaid look more like commercial insurance [open enrollment periods]; drug testing as a condition of eligibility, benefit modifications; changes in the ways that states determine/implement eligibility)?
What are some of the key findings from current §1115 waiver evaluations.
Issues related to data sources, best types of evaluations to suit circumstances/goals, methodologies, standardizations across evaluations, etc.
This session will examine the approach taken to §1332 waivers under the prior and current administrations and provide a landscape of the current state of affairs. In addition, it will explore the goals that federal and state policymakers are trying to achieve through these waivers and understand what outcomes should be evaluated.
Given the stated parameters for developing §1332 waivers, are there some common approaches to evaluating any waivers being proposed to CCIIO as well as for evaluating implemented waivers? What data are needed? What are the challenges in measuring the parameters related to: 1) access to quality care at least as comprehensive and affordable; 2) comparable number of residents provided coverage; and 3) does not contribute to deficit? Are there lessons from §1115 evaluations that can inform §1332 waiver evaluations?

References: §1115
 §1332
 §1115
 §1115
 §1332
 §1332
 §1115
 §1332